| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -1.4 | -2.1 |
| Net income | 1.1 | -2.0 |
| EPS (diluted, $ a share) | $0.04 | $-0.09 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ABVC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Abvc Biopharma, Inc.: key numbers
- Share price
- $0.9400Close, Nov 16
- Market cap
- $25.4M
- Shares outstanding
- 26.98MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Abvc Biopharma, Inc.
All →Abvc Biopharma $4.11M Debt Financing with WallachBeth Capital, LLC
ABVC BioPharma entered into a securities purchase agreement for the sale of original issue discount senior convertible promissory notes in an aggregate principal amount of $4,106,060. The notes carry a 17.5% original issue discount, generating gross proceeds of $3.39 million, and mature on June 30, 2027. Proceeds will be used for working capital and to fund a $625,000 settlement payment to Lind Global Fund II LP.
- Value
- $4.11M
- Counterparty
- WallachBeth Capital, LLC
- Term
- through June 30, 2027